Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
grade B 38.41 2.54% 0.95
QURE closed up 2.54 percent on Tuesday, February 19, 2019, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Mar 13

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical QURE trend table...

Date Alert Name Type % Chg
Feb 19 NR7 Range Contraction 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup 2.54%
Feb 14 Slingshot Bullish Bullish Swing Setup 6.78%
Feb 14 NR7 Range Contraction 6.78%
Feb 14 Upper Bollinger Band Walk Strength 6.78%
Feb 14 Overbought Stochastic Strength 6.78%
Feb 13 Upper Bollinger Band Walk Strength 3.87%
Feb 13 Overbought Stochastic Strength 3.87%
Feb 13 Upper Bollinger Band Touch Strength 3.87%
Feb 12 Pocket Pivot Bullish Swing Setup -2.24%

Older signals for QURE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biopharmaceutical Biology Diseases Gene Therapy Genetics Parkinson's Disease Applied Genetics Gene Delivery Treatment Of Hemophilia Adeno Associated Virus AAV Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B
Is QURE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 43.23
52 Week Low 20.29
Average Volume 358,260
200-Day Moving Average 32.9039
50-Day Moving Average 31.0228
20-Day Moving Average 34.591
10-Day Moving Average 36.468
Average True Range 2.0414
ADX 31.97
+DI 28.6356
-DI 12.6532
Chandelier Exit (Long, 3 ATRs ) 33.7258
Chandelier Exit (Short, 3 ATRs ) 36.3612
Upper Bollinger Band 39.6276
Lower Bollinger Band 29.5544
Percent B (%b) 0.88
BandWidth 29.12087
MACD Line 1.9945
MACD Signal Line 1.8055
MACD Histogram 0.189
Fundamentals Value
Market Cap 981.75 Million
Num Shares 25.6 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -13.62
Price-to-Sales 16.30
Price-to-Book 14.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.59
Resistance 3 (R3) 40.46 39.60 40.22
Resistance 2 (R2) 39.60 39.05 39.67 40.10
Resistance 1 (R1) 39.01 38.71 39.31 39.14 39.98
Pivot Point 38.15 38.15 38.30 38.22 38.15
Support 1 (S1) 37.56 37.60 37.86 37.69 36.84
Support 2 (S2) 36.70 37.26 36.77 36.72
Support 3 (S3) 36.11 36.70 36.60
Support 4 (S4) 36.24